Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Summit Corporation, a UK drug discovery company, has achieved a milestone in the Phase 1 trial of SMT C1100, an oral small molecule compound, for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD).
Subscribe to our email newsletter
Following this achievement, Summit will receive the final payment from a $1.5m funding agreement with US based DMD organizations.
Summit chief executive officer Glyn Edwards said, "The funding will enable completion of the Phase 1 trial this year, after which we will seek an appropriate partner to advance SMT C1100 through proof-of-concept studies to ultimately bring this potential breakthrough therapy to patients with DMD."
SMT C1100 is a potential disease-modifying drug that works by increasing, or upregulating, the amount of a naturally occurring protein called utrophin.
Initiated in May 2012 in healthy volunteers, the Phase 1 dose-escalation study will now progress to the stage where participants receive multiple doses.
A group of US-based DMD organizations, which include the Muscular Dystrophy Association, Charley’s Fund, Cure Duchenne, the Foundation to Eradicate Duchenne, Nash Avery Foundation and Parent Project Muscular Dystrophy, supported the Phase 1 trial.
The company is expecting the results from the trial by the end of 2012.